Prioritizing the Indications in Your Drug Discovery Portfolio

This webinar, we will find out how pharma and biotech companies looking to evaluate compounds and targets across their portfolio can now leverage extensive biological pathway data and advanced bioinformatics, combined with development feasibility and commercial metrics. The result is the ability to explore and prioritize thousands of indications more systematically and cost-effectively.

Видео Prioritizing the Indications in Your Drug Discovery Portfolio канала GENNews